Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease



Status:Recruiting
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:Any
Updated:11/11/2018
Start Date:November 3, 2014
End Date:August 28, 2019
Contact:For site information, send an email with site number to
Email:Contact-Us@sanofi.com

Use our guide to learn which trials are right for you!

A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease

- The primary objective of this study is to characterize the pharmacokinetics of
alglucosidase alfa manufactured at the 4000 L scale in patients who have a confirmed
diagnosis of Pompe disease.

- A secondary objective of this study is to evaluate and explore the relationship between
anti-rhGAA antibody titers and the pharmacokinetics of alglucosidase alfa.

The total study duration per patient will be 4 to 9 weeks that consist of a screening period
(from 2 days to 4 weeks), treatment visit (1 day), and a follow up call (≥30 days).

Inclusion Criteria:

A patient must meet all of the following criteria to be eligible for this study:

- The patient and/or the patient's parent/legal guardian is willing and able to provide
signed informed consent.

- The patient has a confirmed GAA enzyme deficiency from skin, blood, or muscle tissue
and/or 2 confirmed GAA gene mutations.

- Infant and toddler Pompe disease patients can be included in the study only under
condition (minimal body weight) that the trial-related blood loss (including any
losses in the maneuver) will not exceed 3 percent of the total blood volume during a
period of 4 weeks and will not exceed 1 percent at any single time.

- The patient, if female and of childbearing potential, must have a negative pregnancy
test (urine beta-human chorionic gonadotropin) at screening. Note: All female patients
of childbearing potential and sexually mature males must agree to use a medically
accepted method of contraception throughout the study.

- For patients previously treated with alglucosidase alfa the patient has received
alglucosidase alfa for at least 6 months.

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from this study:

- The patient is participating in another clinical study using an investigational
product.

- The patient, in the opinion of the Investigator, is unable to adhere to the
requirements of the study.

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
We found this trial at
6
sites
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Sofia,
Click here to add this to my saved trials